Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mechanistic insights into the liver-brain axis during chronic liver disease

  • Siddle, Matthew
  • Gallego-Durán, Rocío
  • Goel, Deepika
  • Renquist, Benjamin J.
  • Holt, Marie K.
  • Hadjihambi, Anna
The liver is a metabolically flexible tissue, adapting its functions to changes in nutrient availability and physiological states. This adaptability is crucial for maintaining metabolic homeostasis and likely involves communication with the central nervous system through the liver–brain axis. The liver also receives a constant influx of nutrients, hormones and microbial metabolites from the gastrointestinal tract in a multifaceted communication network, the gut–liver–brain axis. Dysregulation of this communication can lead to hepatic encephalopathy and cognitive impairments in early-stage chronic liver disease, such as metabolic dysfunction-associated steatotic liver disease, substantially affecting patient quality of life. This Review examines key signalling pathways along the liver–brain axis: humoral signalling, including metabolites, hepatokines, toxins and inflammation, and neural pathways, focusing on afferent signalling through the common hepatic branch of the vagus nerve. We discuss how each pathway might contribute to behavioural and mood changes in chronic liver disease and the development of hepatic encephalopathy. Although the humoral effects have been studied more extensively, we propose that the afferent vagus nerve is central to liver disease-associated cognitive and behavioural complications. Finally, we highlight how new techniques and tools could advance our understanding of the gut–liver–brain communication that affects behaviour., M.S. is funded by the Wellcome Trust as part of the Neuro-Immune Interactions in Health & Disease Wellcome Trust PhD Programme (218452/Z/19/Z). R.G.D. acknowledges support to ISCIII from grants CD21/00095, PI22/01342, PI19/01404, PI24/02008. B.J.R. is funded by the NIH (NIDDK R01DK132281) and the US Department of Defense (W81XWH-22-2-0043 and PR221455 HT9425-23-1-0810). M.K.H. is funded by the British Heart Foundation (FS/IPBSRF/20/27001) and the Royal Society (RG\R1\241213). A.H. is funded by UKRI, Future Leaders Fellowship (MR/X033287/1) and the Foundation for Liver Research., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deciphering the role of ammonia in MASLD: From a neurotoxin to a metabolic by-product, Descifrando el papel del amoníaco en el MASLD: de neurotoxina a subproducto metabólico

  • Zurita-Palomo, Carola
  • Martín, Franz
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Gallego-Durán, Rocío
Ammonia, a nitrogen-containing compound produced during amino acid catabolism, plays a key role in nitrogen homeostasis. The primary source of ammonia in humans is the gut, where it is produced from dietary sources, luminal bacterial urease activity and glutamine deamination in enterocytes.1 This gut-derived ammonia is transported to the liver via the portal vein, and because ammonia is potentially neurotoxic, rapid and efficient removal is essential. Among others organs, the liver is the main organ responsible for its detoxification via the urea cycle. Ureagenesis occurs specifically in periportal hepatocytes by the action of urea cycle enzymes (UCEs), which involves two mitochondrial enzymes (carbamoyl phosphate synthetase 1 (CPS1) and ornithine transcarbamylase (OTC)) and three cytosolic enzymes (arginosuccinate synthetase (ASS), arginosuccinate lyase (ASL) and arginase 1 (ARG1)). In health, ammonia is converted into urea, which is excreted by the kidneys maintaining the systemic nitrogen balance, The research leading to these results has received funding from Instituto de Salud Carlos III under grant agreements PI24/02008, PI22/01342, from Agencia Estatal de Investigación under grant agreement PID2024-162275OB-I00 and European Partnership for Personalized Medicine under grant agreement EPPERMED2024-496. RGD and DMM are both recipients of EMERGIA fellowships from Consejería de Universidad, Investigación e Innovación from Junta de Andalucía under grant agreements DGP_EMEC_2023_00394 and DGP_EMEC_2023_00472, Peer reviewed